Signal Says Buy Options Insurance on This Biotech

Newly upgraded Exelixis stock could take a breather, if past is prologue

Mar 18, 2019 at 1:06 PM
facebook twitter linkedin

Exelixis, Inc. (NASDAQ:EXEL) shares are fresh off a new high, thanks to some upbeat analyst attention. Specifically, Morgan Stanley upgraded the biotech stock to "equal weight" from "underweight," and hiked its price target to $28 from $20, citing strong prescription trends among other reasons. However, if recent history is any indicator, EXEL bulls may want to consider buying options insurance to guard against a short-term pullback.

EXEL stock surged as high as $25.31 this morning, representing a new annual high. The stock has almost doubled since touching a two-year low of $13.42 in late October, with pullbacks contained by its 60-day moving average. More recently, EXEL last week barreled through recent congestion in the $23-$24 neighborhood. At last check, the security has trimmed its lead to 0.6% to trade at $24.67.

EXEL stock chart March 18

Meanwhile, Exelixis sports relatively inexpensive short-term option premiums right now. The stock's Schaeffer's Volatility Index (SVI) of 37% is higher than just 3% of all other readings from the past year, suggesting EXEL's near-term options are pricing in relatively low volatility expectations at the moment.

Since 2008, there have been six other times when EXEL shares were within 2% of a 52-week high and simultaneously sported an SVI in the bottom 20% of its annual range. After those signals, the stock was lower one-month later two-thirds of the time, averaging a loss of 5.77%, according to data from Schaeffer's Senior Quantitative Analyst Rocky White.

Against this backdrop, now could be an opportune time for Exelixis shareholders to pick up options insurance on the cheap. Specifically, traders should consider buying protective puts on EXEL, which would lock in an acceptable sale price for the shares, should they once again take a turn for the worse. From the security's current perch, another 5.77% pullback would put the biotech around $23.30 in mid-April.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners